Conduct diligence and market landscaping for healthcare/life science companies.
Source early-stage innovation from academic labs, incubators, and emerging biotechs.
Developed company thesis focused on transcription factor-targeted therapeutics.
Led scientific direction and investor engagement.
Led medicinal chemistry and platform strategy for a novel covalent modality; advanced first asset to in vivo proof-of-concept.
Played key leadership role in shaping scientific narrative for fundraising efforts totaling $20M (Curie.Bio, Gordian Ventures).
Initiated and led small-molecule degrader program.
Supported lead optimization for epigenetic and ADC programs in oncology.
Hit-to-lead and lead optimization for target classes within immuno-inflammation.
Member of team to nominate development candidate for RORY inverse agonist.
Discover other experts with similar qualifications and experience
2025 © FRATCH.IO GmbH. All rights reserved.